Literature DB >> 36066396

Overexpression of lncRNA TCLlnc1 in gastric cancer predicts postoperative distant recurrence and poor survival.

Kan Hu1, Yugui Zhang, Jun Rong, Wensheng Deng, Benping Xiao.   

Abstract

TCLlnc1 was characterized as a lncRNA with oncogenic roles in T cell lymphoma, whereas its role in other diseases is unknown. We then explored the involvement of TCLlnc1 in gastric cancer. Paired gastric cancer and nontumor tissues from 66 gastric cancer patients were used to extract total RNA samples, which were used to perform RT-qPCRs to determine the expression of TCLlnc1. Plasma samples from these 66 gastric cancer patients and 66 healthy controls were also used to detect circulating TCLlnc1. Correlations of TCLlnc1 in both plasma and tissue samples with patients' clinical data were analyzed by chi-square t -test. The diagnostic value of TCLlnc1 for early-stage gastric cancer was analyzed with the receiver operating characteristic curve. A 5-year follow-up study was performed to explore the prognostic value of TCLlnc1 for the survival of gastric cancer patients. TCLlnc1 expression in tissue was increased in gastric cancer. Plasma TCLlnc1 was also increased in gastric cancer. Plasma TCLlnc1 was closely correlated with TCLlnc1 in gastric cancer tissues, but not TCLlnc1 in nontumor tissues. TCLlnc1 in plasma was only correlated with tumor distant metastasis, but not other clinical data. TCLlnc1 in plasma showed promising diagnostic value for stage I and II gastric cancer. Increased accumulation of TCLlnc1 was closely correlated with distant recurrence and poor survival during a 5-year follow-up. Therefore, TCLlnc1 is overexpressed in gastric cancer predicts postoperative distant recurrence and poor survival.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36066396      PMCID: PMC9575564          DOI: 10.1097/CAD.0000000000001396

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.389


  18 in total

Review 1.  Progress in gastric cancer.

Authors:  Vivian E Strong
Journal:  Updates Surg       Date:  2018-06-05

2.  Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection.

Authors:  Wen Zhong Liu; Yong Xie; Hong Lu; Hong Cheng; Zhi Rong Zeng; Li Ya Zhou; Ye Chen; Jiang Bin Wang; Yi Qi Du; Nong Hua Lu
Journal:  Helicobacter       Date:  2018-03-07       Impact factor: 5.753

Review 3.  Recent advances in the molecular diagnostics of gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

4.  Gastric cancer: factors affecting survival.

Authors:  Suleyman Orman; Haci Murat Cayci
Journal:  Acta Chir Belg       Date:  2018-03-21       Impact factor: 1.090

Review 5.  A global burden of gastric cancer: the major impact of China.

Authors:  Yongzhan Nie; Kaichun Wu; Jun Yu; Qiaoyi Liang; Xiqiang Cai; Yulong Shang; Jinfeng Zhou; Kaifeng Pan; Liping Sun; Jingyuan Fang; Yuan Yuan; Weicheng You; Daiming Fan
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-04-10       Impact factor: 3.869

Review 6.  LncRNAs: emerging biomarkers in gastric cancer.

Authors:  Yu Gu; Tianxiang Chen; Guangliang Li; Xiongfei Yu; Yimin Lu; Haohao Wang; Lisong Teng
Journal:  Future Oncol       Date:  2015-08-20       Impact factor: 3.404

Review 7.  LncRNA-mediated regulation of cell signaling in cancer.

Authors:  W-X Peng; P Koirala; Y-Y Mo
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

Review 8.  The role of miRNA and lncRNA in gastric cancer.

Authors:  Ning-Bo Hao; Ya-Fei He; Xiao-Qin Li; Kai Wang; Rui-Ling Wang
Journal:  Oncotarget       Date:  2017-07-12

Review 9.  Biomarkers of gastric cancer: Current topics and future perspective.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2018-07-14       Impact factor: 5.742

Review 10.  The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond.

Authors:  Christian Schulz; Kerstin Schütte; Julia Mayerle; Peter Malfertheiner
Journal:  Therap Adv Gastroenterol       Date:  2019-12-18       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.